The Inhibition of Platelet Antiaggregating Activity of Clopidogrel by Atorvastatin Detected by Erythromycin Breath Test: a Metabolic Inhibition of Hepatic Cytochrome P450-3A
Males and females age 18-75 years of age without bias in racial and ethnic background, undergoing percutaneous coronary intervention requiring antiplatelet therapy: 1. Patients presented to cardiology clinic requiring cholesterol lowering agent 2. Patients presented to cardiology clinic requiring antiplatelet agent.
You may not be if
Refusal or inability to give written consent
Allergic reaction to erythromycin
Have known bleeding problems, liver disease, significant lung disease kidney disease
Pregnancy
Psychiatric impairment and documented history of substance abuse
